|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||152.42 - 155.79|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||148.51|
|Earnings Date||Oct 25, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||179.44|
President Trump's healthcare bill may have died in Congress, but that's not stopping him from making changes to Obamacare. Later today, the president is expected to sign an executive order that would let Americans buy insurance across state lines. Yahoo Finance’s Alexis Christoforous and Editor-in-Chief Andy Serwer figure out if the the president’s move will help lower premiums.
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
Vertex Pharmaceuticals Inc., on the brink of a breakthrough that could treat nearly all patients with cystic fibrosis, has done everything an investor could ask for in 2017, including double its market ...
Vertex Pharmaceuticals Incorporated today announced a 10-year, $500 million corporate giving commitment focused on providing patient and caregiver support including access to our medicines; expanding our commitment to science, technology, engineering, arts and math education; developing young physicians and scientists; and investing in our communities.
Vertex Pharmaceuticals Incorporated will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.
There may be short-term volatility because of the health-care overhaul in Washington, but the long-term thesis is intact. By Phil van Doorn.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Vertex Pharmaceuticals, Inc. a score of 59. Our analysis is based on comparing Vertex Pharmaceuticals, Inc. with the following peers – Gilead Sciences, Inc., AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Enzon Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc. and SciClone Pharmaceuticals, Inc. (GILD-US, ... Read more (Read more...)
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
Vertex Pharmaceuticals (VRTX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Vertex Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
In August 2017, the EC (European Commission) approved the label expansion of Alexion Pharmaceuticals' (ALXN) Soliris.
With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio
Analysts at BTIG laid out the bullish case for owning shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) — a "storied" company with a strong growth outlook. BTIG's Dane Leone initiates ...
Vertex is nearing the end of its journey in cystic fibrosis with likely approval of a triple pill in the next couple of years.